Particularly, a downregulation of CDKN1C is generally reported in cancer including gastric [147] and urothelial cancer [148,149], pancreatic adenocarcinomas [150], adrenocortical [151], lung [152], and breast cancer [153] as well as several leukemias [154]. Here, CDKN1C is linked to cancer.